Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Managed Care March 2007 Martin Sipkoff	Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails.
Pharmaceutical Executive February 1, 2013 William Looney	In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer.
Nurse Practitioner August 2010 Virginia Sun	Update on Pancreatic Cancer Treatment Pancreatic cancer is the 10th leading type of all new cancer cases and the fourth leading type of cancer death that affects both men and women.
Pharmaceutical Executive September 1, 2011 Don Creighton	Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement.
Nurse Practitioner October 2009 Wallace et al.	Shedding light on prostate cancer This article will discuss the risk factors, signs and symptoms, diagnosis of prostate cancer, and disease staging and grading, as well as necessary lab and diagnostic tests, treatment options and patient education.
Managed Care August 2007 Martin Sipkoff	Soaring Price of Cancer Drugs Leads Plans To New Approaches Insurers are trying different methods, from pay for performance to promoting preventive care, to hold down cost of chemotherapy drugs.
Pharmaceutical Executive February 1, 2013 William Looney	Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice.
Chemistry World September 7, 2015	Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs.
American Family Physician February 15, 2005 Sunga et al.	Care of Cancer Survivors Cancer survivors are at increased risk for recurrence of their original malignancy. Surveillance following curative cancer treatment generally includes interval history and physical examinations every six months for five years.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
American Family Physician February 15, 2005	Health Care After Cancer Treatment An informative patient hand-out on follow-up cancer care.
Pharmaceutical Executive July 3, 2007 Sarah Houlton	Global Report: Five-Year Survivor: European Edition The UK government's attitude seems to be that oncology treatments are hugely expensive -- and that too much of the National Health Service budget is vanishing into the pockets of drug companies. Will cancer networks fill the gap?
American Journal of Nursing March 2006 Pamela J. Haylock	The Shifting Paradigm of Cancer Care: The Many Needs of Cancer Survivors Are Starting to Attract Attention The complexities of survivorship, and the growing population of survivors who share these challenges has led to an increase awareness of a need for survivorship research on the sequelae of cancer and cancer treatment.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
Managed Care October 2007 Lola Butcher	Can Insurer, Oncology Practice Really Work Together? Premera Blue Cross and a large Spokane oncology practice agree on treatment protocols and on the importance of cost control.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
American Journal of Nursing September 2009 Lockwood-Rayermann et al.	Original Research: Women's Awareness of Ovarian Cancer Risks and Symptoms Objective: To assess how well informed women ages 40 and older are of ovarian cancer symptoms and risk factors.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool May 19, 2011 Brian Orelli	Pfizer Goes for a One-Two Blockbuster Knockout The pharma giant already has Sutent approved to treat kidney cancer, and now it's hoping to follow up that treatment with axitinib.
Pharmaceutical Executive August 1, 2012 Debbie Warner	Adapting to a New Era of Cancer Care Coverage and treatment decisions will be driven by value and defined differently by each stakeholder.
The Motley Fool June 6, 2011 Luke Timmerman	Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off?
Pharmaceutical Executive September 1, 2012 Robin Hertz	The Endless Treadmill of End-of-Life Care Bending the cost curve back to valuing the cycle of life.
The Motley Fool September 9, 2011 Frank Vinluan	GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche.
Chemistry World September 28, 2012 Andrew Turley	Regorafenib approved in US US authorities have approved Stivarga (regorafenib) tablets for the treatment of advanced colorectal cancer.
AskMen.com	Good Health Care News New advice from the American Cancer Society puts a sharper focus on the risks of prostate cancer screening, emphasizing that annual testing can lead to unnecessary biopsies and treatments that do more harm than good.
Scientific American August 2008 Jessica Wapner	Cancer Drug Costs May Help Doctors Select a Treatment In discussing treatments, cancer doctors plan to include cost.
BusinessWeek June 6, 2005 Catherine Arnst	Better Odds Against Breast Cancer New treatments for breast cancer are more effective, and easier to live with
The Motley Fool September 2, 2011 Brian Orelli	Delcath Wants a Do-Over You'd think a drug failing to show an effect would be the worst thing that could happen to a biotech investor, but mixed results are actually much worse.
Nursing Management January 2010 Janet Snapp	Partnering with palliative care The goal of palliative care is to prevent and relieve suffering and to support the best possible quality of life for patients and their families, regardless of the stage of the disease or the need for other therapies.
The Motley Fool June 23, 2009 Brian Orelli	Wonder Drug! Maybe? Get the facts before jumping on this one.
The Motley Fool May 28, 2009 Brian Orelli	Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us.
The Motley Fool May 24, 2010 Brian Orelli	ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse.
BusinessWeek June 21, 2004 Catherine Arnst	Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs.
Chemistry World January 21, 2011 Jennifer Newton	Early lung cancer diagnosis Patients with lung cancer have elevated levels of a specific protein in their blood that could be used as a biomarker for the disease, say scientists from South Korea.
American Family Physician May 15, 2005	Early Prostate Cancer: What You Should Know A patient hand-out on the disease, who is at risk, diagnosis and treatment options.
Fast Company September 14, 2011 Emma Haak	Global E-Health Forum Protecting patients' medical information in the digital age is no easy feat.
BusinessWeek February 4, 2010 Terhune & Weintraub	Take Your Meds, Exercise -- and Spend Billions Washington wants to pump big money into so-called disease management, though there's scant evidence that it works.
American Journal of Nursing August 2009 Fu et al.	Post Breast Cancer Lymphedema: Part 2 The authors discuss current approaches to risk reduction, treatment and management of the condition, and implications for nurses.
Pharmaceutical Executive January 1, 2013 Al Topin	The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author.
BusinessWeek February 16, 2004 Catherine Arnst	Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs.
AskMen.com Jacob Franek	Prostate Cancer Overview Everything you wanted to know and more about prostate cancer in this three-part prostate cancer guide.
BusinessWeek May 27, 2010 Pettypiece & Gibson	Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer."
Nursing January 2011 Carl A. Kirton	HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
AskMen.com Whitney F. Jones	Colon Cancer And Polyps: What You Need To Know It would surprise many to learn that colon cancer is the third leading cause of death by cancer in American men.
AskMen.com Dustin Driver	8 Cancer Myths The following myths about cancer have been debunked by doctors and scientists the world over. So do yourself and your community a favor: read the facts and spread the word.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
The Motley Fool July 16, 2007 Brian Lawler	Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note.
The Motley Fool July 1, 2011 Brian Orelli	Dendreon Is Drama-Free ... for Now For a drug that has had so much drama during its existence, the final decision by the Centers for Medicare and Medicaid Services to pay for Dendreon's prostate cancer treatment Provenge was pretty anticlimactic.